BR112021022503A2 - Métodos de administração de anticorpo anti-cd38 para tratar mieloma múltiplo - Google Patents
Métodos de administração de anticorpo anti-cd38 para tratar mieloma múltiploInfo
- Publication number
- BR112021022503A2 BR112021022503A2 BR112021022503A BR112021022503A BR112021022503A2 BR 112021022503 A2 BR112021022503 A2 BR 112021022503A2 BR 112021022503 A BR112021022503 A BR 112021022503A BR 112021022503 A BR112021022503 A BR 112021022503A BR 112021022503 A2 BR112021022503 A2 BR 112021022503A2
- Authority
- BR
- Brazil
- Prior art keywords
- multiple myeloma
- antibody
- treat multiple
- administration methods
- antibody administration
- Prior art date
Links
- 208000034578 Multiple myelomas Diseases 0.000 title abstract 4
- 206010035226 Plasma cell myeloma Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 238000001802 infusion Methods 0.000 abstract 2
- 229950007752 isatuximab Drugs 0.000 abstract 2
- 238000001990 intravenous administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
métodos de administração de anticorpo anti-cd38 para tratar mieloma múltiplo. a presente invenção refere-se a métodos de tratamento de um indivíduo humano tendo mieloma múltiplo que compreendem administrar ao indivíduo 10 mg/kg de isatuximab por meio de infusão intravenosa, em que o volume de cada infusão de 10 mg/kg de isatuximab é de 250 ml. são também fornecidos métodos de tratamento de um indivíduo humano tendo mieloma múltiplo que compreendem administrar um anticorpo anti-cd38 em ciclos de 28 dias, em que o anticorpo anti-cd38 é administrado nos dias 1, 8, 15, e 22 de um primeiro ciclo de 28 dias, em que o anticorpo anti-cd38 é administrado nos dias 1 e 15 de cada ciclo de 28 dias após o primeiro ciclo de 28 dias; e em que o anticorpo anti-cd38 é administrado em uma dose de 10 mg/kg ou 20 mg/kg.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962847825P | 2019-05-14 | 2019-05-14 | |
| US201962860739P | 2019-06-12 | 2019-06-12 | |
| US201962899088P | 2019-09-11 | 2019-09-11 | |
| EP20305223 | 2020-03-03 | ||
| PCT/US2020/032754 WO2020232173A1 (en) | 2019-05-14 | 2020-05-13 | Methods of administering anti-cd38 antibody to treat multiple myeloma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021022503A2 true BR112021022503A2 (pt) | 2021-12-28 |
Family
ID=71094805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021022503A BR112021022503A2 (pt) | 2019-05-14 | 2020-05-13 | Métodos de administração de anticorpo anti-cd38 para tratar mieloma múltiplo |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210171650A1 (pt) |
| EP (1) | EP3969004A1 (pt) |
| JP (1) | JP2022532356A (pt) |
| KR (1) | KR20220008305A (pt) |
| CN (1) | CN114080233A (pt) |
| AU (1) | AU2020274169A1 (pt) |
| BR (1) | BR112021022503A2 (pt) |
| CA (1) | CA3140034A1 (pt) |
| CO (1) | CO2021016606A2 (pt) |
| IL (1) | IL287832A (pt) |
| MA (1) | MA55967A (pt) |
| MX (1) | MX2021013910A (pt) |
| SG (1) | SG11202112513YA (pt) |
| TW (1) | TW202108624A (pt) |
| WO (1) | WO2020232173A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3197381A1 (en) * | 2020-11-03 | 2022-05-12 | Sanofi-Aventis U.S. Llc | Use of isatuximab for the treatment of multiple myeloma |
| AU2022253256A1 (en) * | 2021-04-08 | 2023-11-16 | Artiva Biotherapeutics, Inc. | Treatment of cancer with nk cells and a cd38-targeted antibody |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| US10342869B2 (en) * | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| EP3917961A1 (en) * | 2019-01-28 | 2021-12-08 | Sanofi | Methods of treating multiple myeloma |
-
2020
- 2020-05-13 AU AU2020274169A patent/AU2020274169A1/en active Pending
- 2020-05-13 MA MA055967A patent/MA55967A/fr unknown
- 2020-05-13 CN CN202080049892.8A patent/CN114080233A/zh active Pending
- 2020-05-13 EP EP20733081.2A patent/EP3969004A1/en active Pending
- 2020-05-13 BR BR112021022503A patent/BR112021022503A2/pt unknown
- 2020-05-13 US US15/931,466 patent/US20210171650A1/en active Pending
- 2020-05-13 KR KR1020217040398A patent/KR20220008305A/ko unknown
- 2020-05-13 WO PCT/US2020/032754 patent/WO2020232173A1/en active Application Filing
- 2020-05-13 MX MX2021013910A patent/MX2021013910A/es unknown
- 2020-05-13 CA CA3140034A patent/CA3140034A1/en active Pending
- 2020-05-13 SG SG11202112513YA patent/SG11202112513YA/en unknown
- 2020-05-13 JP JP2021567963A patent/JP2022532356A/ja active Pending
- 2020-05-14 TW TW109116104A patent/TW202108624A/zh unknown
-
2021
- 2021-11-04 IL IL287832A patent/IL287832A/en unknown
- 2021-12-07 CO CONC2021/0016606A patent/CO2021016606A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202108624A (zh) | 2021-03-01 |
| MA55967A (fr) | 2022-03-23 |
| EP3969004A1 (en) | 2022-03-23 |
| AU2020274169A1 (en) | 2022-01-20 |
| CO2021016606A2 (es) | 2022-04-29 |
| CA3140034A1 (en) | 2020-11-19 |
| CN114080233A (zh) | 2022-02-22 |
| MX2021013910A (es) | 2022-03-11 |
| IL287832A (en) | 2022-01-01 |
| KR20220008305A (ko) | 2022-01-20 |
| WO2020232173A1 (en) | 2020-11-19 |
| SG11202112513YA (en) | 2021-12-30 |
| US20210171650A1 (en) | 2021-06-10 |
| JP2022532356A (ja) | 2022-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022015499A (es) | Metodos para tratar la enfermedad de crohn y la colitis ulcerosa. | |
| JOP20200156A1 (ar) | إيسكيتامين لعلاج الاكتئاب | |
| BR112015029918A2 (pt) | uso de alta dose de pridopidina para tratar a doença de huntington | |
| BRPI0513200A (pt) | uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas | |
| NO20055880L (no) | Memantin orale doseringsformer | |
| AR104771A1 (es) | Inhalador de polvo seco | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| BR112019005168A2 (pt) | composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente que sofre ou susceptível de sofrer de um distúrbio respiratório, para melhoria da estabilidade de uma composição farmacêutica e do desempenho de aerossolização de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica | |
| BR112017006272A2 (pt) | composição farmacêutica para tratar colite ulcerativa. | |
| BR112021022503A2 (pt) | Métodos de administração de anticorpo anti-cd38 para tratar mieloma múltiplo | |
| RU2016149316A (ru) | Лечение ревматоидного артрита | |
| BR112023006337A2 (pt) | Produto farmacêutico, uso de um conjugado anticorpo anti-her2-fármaco ou um inibidor seletivo de parp1, e, método de tratamento do câncer | |
| CY1124236T1 (el) | Διαλυμα εγχυσης λεβοντοπα | |
| MX2021006242A (es) | Formulaciones de capsula. | |
| BR112022000734A2 (pt) | Método para tratar câncer em um paciente, uso de composto 1, e, composto 1 | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
| PL431290A1 (pl) | Bezpieczna metoda podawania substancji ślimakom w formie iniekcji dożylnych | |
| Iida | Hypersensitivity: case report | |
| Семиволос et al. | New preparation “Leksoflon” for the treatment of cows with acute postpartum endometritis | |
| AR114012A1 (es) | Método para proporcionar terapia de celiprolol a un paciente | |
| Saghafi | Recurrent priapism: case report | |
| AR102903A1 (es) | Inhalador de polvo seco | |
| RU2003125593A (ru) | Способ лечения острого вирусного гепатита в | |
| UA84047U (ru) | Способ лечения вторичных нарушений системы гемостаза у больных гемофилией с большими интрамышечными гематомами |